Corporate Events

ASKA Pharmaceutical Holdings Co.,Ltd., ¥ 32.0, Cash Dividend, Sep-29-2026

ASKA Pharmaceutical Holdings Co.,Ltd., Board Meeting, Jul 13, 2026. Agenda: To Notice Concerning Disposal of Treasury Shares for Restricted Stock Incentives through Employee Shareholding Association.

On June 25, 2026, Asuka Pharmaceutical Holdings Co., Ltd. announced that it held its annual general meeting of shareholders on June 24, 2026, and declared voting results. Accordingly, the shareholder concerns the "Election of 2 directors who are not Audit Committee members," specifically nominating James B. Rosenwald III and Shiro Hayashi was rejected.

ASKA Pharmaceutical Holdings Co. Ltd. at its 5th Ordinary General Meeting of Shareholders held on June 24, 2026, approved partial amendments to the Articles of Incorporation.

ASKA Pharmaceutical Holdings Co. Ltd. announced in the March 2, 2026 press release “Notice regarding Transition to Company with Audit Committee,” plans to transition to a company with an audit committee, subject to approval at the 5th Ordinary General Meeting of Shareholders to be held on June 24, 2026. Accordingly, at a meeting of the Board of Directors held May 25, 2026, the Company resolved to submit a proposal for “Partial Amendments to the Articles of Incorporation” to the 5th Ordinary General Meeting of Shareholders. The Company decided to incorporate this corporate philosophy into its Articles of Incorporation to clearly affirm that this fundamental principle of the Company will remain unchanged in the future and to clearly communicate such principle to the various stakeholders with whom it interacts through business activities. As announced in the March 2, 2026 press release “Notice regarding Transition to Company with Audit Committee,” the Company plans to transition to a company with an audit committee, subject to approval at the 5th Ordinary General Meeting of Shareholders, in order to further improve management transparency and accelerate decision-making. Accordingly, the Company decided to make the necessary changes, including the establishment of new provisions regarding the Audit & Supervisory Committee and Audit & Supervisory Committee Members, as well as the deletion of provisions regarding the Audit & Supervisory Board and Audit & Supervisory Board Members. The contents of the amendments are as described in the Attachment. Date of the General Meeting of Shareholders to amend the Articles of Incorporation: June 24, 2026 (planned). Effective date of the amendments to the Articles of Incorporation: June 24, 2026 (planned).

ASKA Pharmaceutical Holdings Co.,Ltd. announced that they will report Q1, 2027 results on Aug 04, 2026

ASKA Pharmaceutical Holdings Co.,Ltd. expected to report Q1 2027 results on August 3, 2026. This event was calculated by S&P Global (Created on May 27, 2026).

ASKA Pharmaceutical Holdings Co.,Ltd., Board Meeting, May 25, 2026. Agenda: To consider regarding Partial Amendments to Articles of Incorporation.

ASKA Pharmaceutical Holdings Co.,Ltd. announced change in Dividend Policy. Before the Change: As a performance-linked profit distribution strategy, the Company indicates a consolidated dividend payout benchmark ratio of 30%. In addition, the Company's policy is to maintain stable dividends while providing performance-linked returns to shareholders, with a minimum annual dividend of JPY 30 per share. After the Change: As part of the performance-linked profit distribution strategy, the Company provides shareholder returns with a payout ratio of approximately 40% as a guideline. The Company aims to improve dividend levels in line with profit growth. In addition, to clearly demonstrate its commitment to returning profits to shareholders, the Company will introduce a progressive dividend policy (excluding special dividends) and, in principle, will not reduce dividends, thereby striving to maintain stable dividends. Reasons for Change: The Company considers the return of profits to shareholders to be a key management priority. In the Medium-Term Management Plan 2028, which will begin in FY2026, the Company will consider flexibly acquiring its own shares with a target total shareholder return ratio of 40%. Based on these policies, during this Medium-Term Management Plan period, the Company will revise its dividend policy by introducing a progressive dividend (excluding special dividends), with the aim of further enhancing shareholder returns and increasing the stability and predictability of dividends.

ASKA Pharmaceutical Holdings Co.,Ltd. provided dividend guidance of JPY 33.00 per share for the Fiscal year ending March 31, 2027 as compared to JPY 33.00 per share payable to same period prior year.

ASKA Pharmaceutical Holdings Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2027. For the period, the company expects Net sales to be JPY 73,000 million, Operating profit to be JPY 6,200 million, Profit attributable to owners of parent to be JPY 4,800 million and Basic earnings per share to be JPY 169.11.

ASKA Pharmaceutical Holdings Co.,Ltd. proposed dividend of JPY 33.00 per share for the Fiscal year ended March 31, 2026 as compared to JPY 30.00 per share paid a year ago. Record date is March 31, 2026. Scheduled date of annual general meeting of shareholders is June 24, 2026. Scheduled date to commence dividend payments is June 25, 2026. The Company provided dividend guidance of JPY 32.00 per share for the end of second quarter of fiscal year ending March 31, 2027 as compared to JPY 27.00 per share paid a year ago.

ASKA Pharmaceutical Holdings Co. Ltd. announced Mr. Kazuhiro Chiku, current Audit & Supervisory Board Member, is scheduled to retire at the conclusion of the 5th Ordinary General Meeting of Shareholders scheduled to be held on June 24, 2026.

ASKA Pharmaceutical Holdings Co.,Ltd. announced that they will report fiscal year 2026 results on May 11, 2026

FTS AMBROSE HOLDINGS, INC. announced that it has received a round of funding on April 14, 2026. The transaction included participation from returning investor, ASKA Pharmaceutical Holdings Co.,Ltd. increased its stake from 21% to 30% for 1,575 shares. The company has issued common shares in the transaction

On May 11, 2026, Asuka Pharmaceutical Holdings Co., Ltd. announced that it received a written notice from Nippon Active Value Fund Plc’s stating its intention to submit a shareholder proposal at the scheduled 5th Annual General Meeting of Shareholders on June 24, 2026. The shareholder proposal concerns the "Election of 2 directors who are not Audit Committee members," specifically nominating James B. Rosenwald III and Shiro Hayashi. The Board of Directors, based on the recommendations of the Group Nomination Committee composed entirely of independent outside directors, resolved to oppose the shareholder proposal. The Board’s opposition is grounded in the view that the proposal does not enhance the company’s medium- to long-term corporate value or maximize the common interests of shareholders. The Board cited that the Group Nomination Committee had already selected candidates with expertise in pharmaceutical management and global business, and that the shareholder proposal candidates were found not to meet the company’s independence criteria and lacked the expected qualities and roles. Additionally, the Board expressed concerns about potential conflicts of interest, noting that Dalton and related parties, who hold over 20% of the company’s voting rights and are closely associated with the proposed candidates, have previously demanded a management buyout and threatened a tender offer, actions which the Board believes could favor Dalton’s interests over those of general shareholders. Nippon Active Value Fund Plc, maintains that its nominees would strengthen the independence and objectivity of the Board and contribute to maximizing shareholder interests, while the Board urges shareholders to vote against the proposal.

ASKA Pharmaceutical Holdings Co.,Ltd., Annual General Meeting, Jun 24, 2026.

ASKA Pharmaceutical Holdings Co.,Ltd., Board Meeting, Jun 24, 2026. Agenda: To consider the Personnel Changes in Board Members and Corporate Officers.

ASKA Pharmaceutical Holdings Co.,Ltd., 2026 Earnings Call, May 20, 2026

ASKA Pharmaceutical Holdings Co.,Ltd., Board Meeting, May 11, 2026. Agenda: To consider the Notice Concerning the Opinion of the Board of Directors of the Company on the Shareholder Proposal.

Insilico Medicine, a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), announced a strategic research collaboration with ASKA Pharmaceutical Co. Ltd., a specialized pharmaceutical company with a strong focus on internal medicine, obstetrics, and gynecology. This partnership aims to identify novel therapeutic targets with high drug development potential for challenging gynecological conditions, including endometriosis, uterine fibroids, and adenomyosis, by leveraging Insilico's proprietary AI-driven target identification engine, PandaOmics. This collaboration combines ASKA's deep expertise in gynecological therapeutics with Insilico Medicine's advanced AI-driven biological analytics capabilities to address major unmet medical needs affecting hundreds of millions of patients worldwide and to accelerate the development of innovative solutions. Under the partnership, Insilico will leverage PandaOmics to identify and explore disease hypotheses, while ASKA will validate the AI-predicted therapeutic targets with high translational potential. The project will be led by the Target Discovery team with Dr. Frank Pun, Head of Insilico Medicine's Hong Kong site. The team recently unveiled Target Identification Pro (TargetPro), an AI-driven framework that accelerates therapeutic target discovery by integrating multi-modal data into disease-specific models. By identifying context-dependent predictive patterns, TargetPro outperforms existing target identification models in accurately predicting which targets are most likely to advance to clinical stages. The framework goes beyond validating established clinical targets to nominate novel, high-potential candidates optimized for immediate preclinical validation. Notably, ASKA has been a long-term user of Insilico's AI software. Through this expanded partnership, Insilico and ASKA will apply these proven AI methodologies to navigate the complex biological landscapes of endometriosis, uterine fibroids and adenomyosis, providing a clear roadmap for the next generation of treatments, further underscoring both parties' shared commitment and aligned goals to advance innovation in women's health.

ASKA Pharmaceutical Holdings Co.,Ltd., Board Meeting, Mar 02, 2026. Agenda: To resolve transition to a company with an audit committee, subject to approval at the fifth Ordinary General Meeting of Shareholders to be held on June 24, 2026.

ASKA Pharmaceutical Holdings Co.,Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 54,486 million compared to JPY 49,926 million a year ago. Net income was JPY 3,904 million compared to JPY 4,098 million a year ago. Basic earnings per share from continuing operations was JPY 137.59 compared to JPY 144.59 a year ago.

ASKA Pharmaceutical Holdings Co.,Ltd. expected to report Fiscal Year 2026 results on May 20, 2026. This event was calculated by S&P Global (Created on May 13, 2026).

ASKA Pharmaceutical Holdings Co.,Ltd. announced that they will report Q3, 2026 results on Feb 02, 2026

ASKA Pharmaceutical Holdings Co.,Ltd. announced dividend of JPY 27.00 per share for the second quarter of Year ending March 31, 2026 against JPY 25.00 per share paid a year ago. Scheduled date to commence dividend payments is November 28, 2025.

ASKA Pharmaceutical Holdings Co.,Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the period, Company now expects Net sales to be JPY 71,000 million, Operating profit to be JPY 6,000 million, Profit attributable to owners of parent to be JPY 5,200 million and Earnings per share to be JPY 176.22 against previous guidance of Net sales to be JPY 75,000 million, Operating profit to be JPY 6,800 million, Profit attributable to owners of parent to be JPY 5,000 million and Earnings per share to be JPY 183.44. Reason for the Revisions: Regarding the sales transactions of imported products procured from outside Vietnam and sold domestically by the Company's Vietnamese subsidiary, Ha Tay Pharmaceutical Joint Stock Company(hereinafter, "Hataphar"), the consolidated statement of income for the first quarter of FY2025 recorded the total amount as net sales. However, after reviewing the above transaction, the Company determined that Hataphar does not control the goods or services to be transferred to the customer and that the transaction falls under the category of an "agent" that provides only the service of arranging these goods or services. In accordance with the Group's accounting policies, the Company has therefore decided to amend its sales recording method to a net basis, whereby the amount paid to suppliers is deducted from th amount received from customers. Consequently, the forecasted net sales have been reviseddownward from the previously announced figure.

ASKA Pharmaceutical Holdings Co.,Ltd., ¥ 28.0, Cash Dividend, Mar-30-2026

ASKA Pharmaceutical Holdings Co.,Ltd. expected to report Q3 2026 results on February 3, 2026. This event was calculated by S&P Global (Created on December 2, 2025).

ASKA Pharmaceutical Holdings Co.,Ltd., Board Meeting, Nov 04, 2025. Agenda: To consider to revise the full-year consolidated performance forecasts for FY2025 announced on May 12, 2025.

ASKA Pharmaceutical Holdings Co.,Ltd., Q2 2026 Earnings Call, Nov 11, 2025

ASKA Pharmaceutical Holdings Co.,Ltd. announced that they will report Q2, 2026 results on Nov 04, 2025

ASKA Pharmaceutical Co., Ltd. and Daiichi Sankyo Healthcare Co., Ltd. jointly announce the marketing authorization and distribution as a switch to OTC use of the emergency contraceptive pill "NORLEVO®?", a trademark owned by Perrigo Company plc. Through the collaboration of ASKA, Daiichi Sankyo Healthcare, and Perrigo Company plc, a significant step is being taken to empower Japanese women in the area of reproductive health. Driven by a shared mission to enable informed choices, the switch to OTC use of NORLEVO®? marks a key milestone in advancing Sexual Reproductive Health and Rights (SRHR), reinforcing commitment to self-care, accessibility, and individual well-being. The impact of this matter on FY2025 is currently being examined. If any impact arises, it will be promptly disclosed.